Methadone: Nursing Drug Guide, Respiratory Depression & QT Prolongation

Methadone is available as generic methadone hydrochloride and multiple branded products. Formulations and concentrations differ—oral liquid, tablets, dispersible tablets, and parenteral products are not interchangeable without pharmacy conversion.

Common names include Methadose, Dolophine, and various methadone hydrochloride oral solutions and concentrates. Institutional opioid treatment program (OTP) protocols govern dispensing for addiction treatment in many regions.

Methadone is a long-acting opioid agonist used when benefits outweigh risks under specialist oversight. Nurses most often encounter it in opioid treatment programs, addiction medicine units, and inpatient pain services.

↔On a small screen, swipe or scroll sideways to see the full table.

Methadone is a full mu-opioid receptor agonist with N-methyl-D-aspartate (NMDA) antagonist activity. It suppresses opioid withdrawal, reduces craving, and provides analgesia. Unlike short-acting opioids, methadone has a long elimination half-life and accumulates with repeated dosing—so the same milligram dose becomes more potent over the first days of therapy until steady state is approached.

Labeling emphasizes that population equianalgesic conversion ratios to other opioids (including morphine or hydrocodone) are not accurate for individuals—overestimating methadone when rotating opioids has caused fatal respiratory depression.

All methadone dosing must follow prescriber orders, product labeling, OTP regulations where applicable, and institutional policy. The examples below reflect methadone hydrochloride tablet labeling—other formulations may differ.

Missed dose: Not specified in the reviewed prescribing information as a single universal rule for all settings. For maintenance patients, missed doses increase withdrawal and relapse risk—contact prescriber/OTP per program protocol; do not double doses.

Discontinuation: Taper slowly for pain or maintenance discontinuation. Maintenance taper reductions are generally less than 10% of the established dose with 10–14 days between reductions per labeling; relapse risk is high after stopping maintenance.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Confirm indication (MAT vs chronic pain) and exact product/concentration—never substitute liquid, tablet, or dispersible strengths without pharmacy verification
• Review respiratory status, baseline RR, SpO₂, and history of COPD, sleep apnea, or hypoventilation
• Screen MAR and home meds for benzodiazepines (e.g. lorazepam, diazepam), alcohol, sedatives, gabapentinoids, and other opioids
• Assess QT risk: baseline ECG when indicated, electrolytes (especially potassium), cardiac history, and QT-prolonging co-medications
• Perform medication reconciliation—note recent opioid doses before rotation or induction
• Check hepatic history (cirrhosis), hypersensitivity, pregnancy/lactation plans, and access to overdose reversal agent
• Verify whether patient is opioid-tolerant when used for pain—methadone is not a first-line opioid for opioid-naïve patients per labeling limitations

Contraindications

• Significant respiratory depression
• Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment
• Known or suspected gastrointestinal obstruction, including paralytic ileus
• Hypersensitivity to methadone

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Oral (MAT): Witness dosing when program policy requires. Document time, dose, formulation, and patient response. For oral liquid, use calibrated devices only—concentrations vary (e.g., 10 mg/mL vs 1 mg/mL errors are catastrophic).

• Follow high-alert medication administration principles—independent double-checks per institutional policy for opioid liquids and dose changes
• Store securely; accidental pediatric ingestion can cause fatal respiratory depression
• Do not crush or split dispersible/tablet products unless pharmacy approves—bioavailability may differ
• IV/IM methadone in hospital settings requires protocol-driven dosing and monitoring—institutional protocols may vary

• Reduction of opioid withdrawal signs (lacrimation, rhinorrhea, myalgias, GI upset) without excessive sedation once stabilized
• 24-hour suppression of withdrawal and reduced illicit opioid craving on maintenance doses
• Stable RR and oxygenation between doses when co-sedating drugs are minimized
• For pain: improved function and analgesia with tolerable side effects—reassess need for continued opioid therapy periodically

Escalate immediately for respiratory compromise, severe sedation, syncope, or suspected overdose. Coordinate with prescriber, pharmacy, and emergency services per facility protocol.

• Bradypnea, difficulty breathing, hypoxemia, cyanosis, or inability to arouse
• Altered mental status, pinpoint pupils with overdose pattern, or coma
• Palpitations, syncope, dizziness, or new arrhythmia—possible QT prolongation / torsades de pointes
• Severe nausea with sedation shortly after dose increase—may signal toxicity, not simple side effect
• Child or visitor with accidental ingestion—treat as opioid emergency
• Suspected diversion, duplicate dosing, or patient taking extra liquid concentrate—verify with pharmacy/OTP immediately

↔On a small screen, swipe or scroll sideways to see the full table.

Methadone overdose may present with respiratory depression, sedation progressing to coma, pinpoint pupils, hypotension, and death. Because methadone is long-acting, toxicity may evolve or recur after initial improvement.

Antidote / reversal

Overdosage priorities per labeling: reestablish a patent airway and assisted or controlled ventilation, then supportive care (oxygen, vasopressors as indicated). Opioid antagonists such as naloxone are specific antidotes for clinically significant respiratory or circulatory depression. Naloxone effects are temporary—patients need prolonged monitoring because methadone outlasts a single reversal dose; repeated naloxone and emergency care per protocol are often required.

• Methadone vs morphine—both are opioids but methadone accumulation and conversion errors are a leading cause of methadone fatalities; verify name, dose, and concentration
• Oral liquid concentration—10 mg/mL vs 1 mg/mL or mg vs mL confusion; use only pharmacy-labeled oral syringes
• Methadone vs methylphenidate or metolazone—verify spelling on orders and MAR
• Tablet strength mix-ups—5 mg, 10 mg, and dispersible strengths are not interchangeable without prescriber approval
• Rotation from other opioids—do not use crude online converters; consult pharmacist and use conservative labeling tables
• Take-home bottles—teach patients to store separately from other household liquids; use only the dispensed measuring device

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Respiratory rate, SpO₂, sedation level, and ability to arouse—especially first 24–72 h after initiation or dose increases per labeling emphasis
• Withdrawal and intoxication signs using program scales; use pain assessment tools when methadone is used for analgesia
• ECG and electrolytes (potassium, magnesium) when QT risk factors or interacting drugs are present
• Liver function tests when clinically indicated—many MAT patients have viral hepatitis comorbidity
• Constipation, adherence, diversion concerns, and take-home bottle counts per OTP policy

Document

• Dose, formulation, concentration (for liquids), route, time, witnessed administration, and patient response
• Induction titration steps and cumulative daily totals—especially day 1–7
• CNS depressant reconciliation, naloxone education/dispensing, and emergency instructions (local protocol—neutral wording for international readers)
• ECG results and prescriber notifications for QT concerns

• Methadone can slow breathing—risk is highest when starting or increasing doses and when combined with alcohol, sleeping pills, or other sedatives unless your prescriber directs otherwise
• Do not take extra doses or someone else’s dose—accumulation can cause delayed overdose
• Use only the measuring device provided with liquid methadone; store locked away from children
• Carry and know how to use an opioid overdose reversal agent; seek emergency care after use—effects may wear off before methadone does
• Report palpitations, fainting, severe sleepiness, or trouble breathing immediately
• Do not stop methadone suddenly—contact your OTP or prescriber for taper to avoid withdrawal and relapse

Do not give and contact the prescriber, pharmacist, or OTP clinician when:

Hold parameters may vary by OTP, pain service, or institutional protocol. Follow prescriber orders and pharmacy guidance.

Practice NCLEX-style clinical judgment practice for methadone using a tabbed MAT case (MAR, labs, vitals/history, nursing notes), then priority action, cue recognition (delayed respiratory depression and CNS depressants), trend interpretation after intervention, matrix urgency sorting, clinical judgment on accumulation, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.